CHAPTER
10
LONG-LIVED TANGIBLE AND INTANGIBLE
ASSE
T
S
Questions, Exercises, and Problems: Answers and
S
ol
u
tio
ns
10.1 See the text or the glossary at the end of the book.
10.2 The central concept underlying GAAP for these three items is the ability to identify and reliably
measure expected future benefits. The self-constructed building has physical substance and the
accountant can observe the effect of an expenditure on the physical structure of the building. The
building provides evidence of future benefits. Research and development (R&D) expenditures may give
rise to an intangible, such as a patent on a new technology. The accountant cannot, however, observe the
physical creation of an asset with future benefits when a firm makes R&D expenditures. Thus, reliably
identifying and measuring future benefits is problematic. U.S. GAAP does not permit recognition of an
asset for research and development expenditures. Expenditures on software development present an
in-between case. The programming underlying the software is embedded in a computer but the
accountant can observe how well the software works. When the software has not yet reached the stage of
technological feasibility, future benefits are uncertain. Thus, U.S. GAAP treats expenditures up to this
point as expenses of the period when incurred. When software reaches the point of technological
feasibility, future benefits become more certain. U.S. GAAP, therefore, permits firms to capitalize
software development expenditures after this point.
10.3 The central concept underlying U.S. GAAP for these three items is the ability to identify
and reliably measure expected future benefits. Expenditures to research new drugs may give rise to future
benefits, but identifying the existence of those future benefits while research progresses is problematic.
Thus, U.S. GAAP requires immediate expensing of research and development expenditures. The
external market transaction for a patent on a new drug validates both the existence and fair value of the
patent. U.S. GAAP, therefore, recognizes the patent as an asset. In- process R&D has characteristics of
the previous two cases. Whether the in- process project will yield future benefits is uncertain, suggesting
that firms should expense such expenditures at the time of acquisition. An external market transaction
between independent parties suggests the existence of future benefits, supporting recognition of an asset
until such time as the status of the research project becomes more certain. FASB Statement No.141
(Revised) requires firms to recognize as an asset the fair value of in- process R&D acquired in a corporate
acquisition, placing greater weight on the evidence provided by the external market transaction than on the
uncertainty of future benefits.
10.4 Over the life of the project, income is the same regardless of whether the firm capitalizes
interest or expenses it. Capitalizing and then amortizing interest versus expensing it affects the timing but
not the total amount of income. Capitalizing interest defers expense from the construction period to the
periods of use. This increases income in the years of construction and decreases it in the periods of use.
In periods of use, depreciation charges are larger.
10.5 A long-lived asset with a finite life is expected to provide benefits for a limited amount of
time. Benefits will eventually decline to zero, either because of physical use, obsolescence, or
disposal. Firms depreciate or amortize assets with finite lives. Note that firms must estimate the